Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1979 Sep;25(3):831–837. doi: 10.1128/iai.25.3.831-837.1979

Modified polyriboinosinic-polyribocytidylic acid complex: sustained interferonemia and its physiological associates in humans.

K J Champney, D P Levine, H B Levy, A M Lerner
PMCID: PMC414523  PMID: 500189

Abstract

Fourteen patients with severe viral illnesses were given intravenous infusions of a modified interferon inducer, polyriboinosinic-polyribocytidylic acid-poly-L-lysine complexed with carboxymethylcellulose [poly)I:C.LC)], during a phase 1 clinical trial. The first eight patients received 0.15 to 0.30 mg of poly(I:C.LC) per kg of body weight daily for 5 consecutive days, and another received two courses separated by 1 week. A second group of five patients was given single intravenous infusions of 0.10 to 0.15 mg of poly(I:C.LC) per kg. Interferon was detectable in the serum 8 to 16 h after injection. Titers ranged from 15 to 800 U/ml and varied directly with the dose of poly(I:C.LC). Interferonemias persisted for 12 to 48 h. In patients receiving 5-day courses of poly(I:C.LC), lower levels of serum interferon (0 to 160 U/ml) occurred on days 2 through 5, characteristic of a hyporesponsive state. An exception was a 69-year-old patient with disseminated varicella zoster, multiple myeloma, and renal insufficiency whose serum contained 3,150 U of interferon per ml on day 3 of 0.3 mg of poly(I:C.LC) per kg. Fever (39 to 40.5 degrees C, rectally; 13 of the 14 patients) peaked 3 to 8 h after completion of infusions. Other toxic effects included lymphopenia (10 of the 14 patients), hypotensive episodes (7 of the 14 patients), and minor elevations of serum glutamicoxalacetic transaminase and lactic dehydrogenase.

Full text

PDF
831

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahström L., Dohlwitz A., Strander H., Carlström G., Cantell K. Letter: Interferon in acute leukaemia in children. Lancet. 1974 Feb 2;1(7849):166–167. doi: 10.1016/s0140-6736(74)92458-1. [DOI] [PubMed] [Google Scholar]
  2. Arvin A. M., Yeager A. S., Merigan T. C. Effect of leukocyte interferon on urinary excretion of cytomegalovirus by infants. J Infect Dis. 1976 Jun;133 (Suppl):A205–A210. doi: 10.1093/infdis/133.supplement_2.a205. [DOI] [PubMed] [Google Scholar]
  3. Catalano L. W., Jr, Baron S. Protection against herpes virus and encephalomyocarditis virus encephalitis with a double-stranded RNA inducer of interferon. Proc Soc Exp Biol Med. 1970 Feb;133(2):684–687. doi: 10.3181/00379727-133-34544. [DOI] [PubMed] [Google Scholar]
  4. Cathala F., Baron S. Interferon in rabbit brain, cerebrospinal fluid and serum following administration of polyinosinic-polycytidylic acid. J Immunol. 1970 Jun;104(6):1355–1358. [PubMed] [Google Scholar]
  5. Cortada de de la Peña N., de Lustig E. S. Interferon production by leukocytes cultures from neoplastic patients. Eur J Cancer. 1974 Mar;10(3):189–192. doi: 10.1016/0014-2964(74)90153-4. [DOI] [PubMed] [Google Scholar]
  6. De Clercq E., Edy V. G., De Vlieger H., Eeckels R., Desmyter J. Intrathecal administration of interferon in neonatal herpes. J Pediatr. 1975 May;86(5):736–739. doi: 10.1016/s0022-3476(75)80360-x. [DOI] [PubMed] [Google Scholar]
  7. DuBuy H. G., Johnson M. L., Buckler C. E., Baron S. Relationship between dose size and dose interval of polyinosinic polycytidylic acid and interferon hyporesponsiveness in mice. Proc Soc Exp Biol Med. 1970 Nov;135(2):340–344. doi: 10.3181/00379727-135-35047. [DOI] [PubMed] [Google Scholar]
  8. Emödi G., Just M., Hernandez R., Hirt H. R. Circulating interferon in man after administration of exogenous human leukocyte interferon. J Natl Cancer Inst. 1975 May;54(5):1045–1049. [PubMed] [Google Scholar]
  9. Emödi G., O'Reilly R., Müller A., Everson L. K., Binswanger U., Just M. Effect of human exogenous leukocyte interferon in cytomegalovirus infections. J Infect Dis. 1976 Jun;133 (Suppl):A199–A204. doi: 10.1093/infdis/133.supplement_2.a199. [DOI] [PubMed] [Google Scholar]
  10. Emödi G., Rufli T., Just M., Hernandez R. Human interferon therapy for herpes zoster in adults. Scand J Infect Dis. 1975;7(1):1–5. doi: 10.3109/inf.1975.7.issue-1.01. [DOI] [PubMed] [Google Scholar]
  11. Epstein L. B., Salmon S. E. The production of interferon by malignant plasma cells from patients with multiple myeloma. J Immunol. 1974 Mar;112(3):1131–1138. [PubMed] [Google Scholar]
  12. Field A. K., Tytell A. A., Piperno E., Lampson G. P., Nemes M. M., Hilleman M. R. Poly I:C, an inducer of interferon and interference against virus infections. Medicine (Baltimore) 1972 May;51(3):169–174. doi: 10.1097/00005792-197205000-00002. [DOI] [PubMed] [Google Scholar]
  13. Greenberg H. B., Pollard R. B., Lutwick L. I., Gregory P. B., Robinson W. S., Merigan T. C. Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. N Engl J Med. 1976 Sep 2;295(10):517–522. doi: 10.1056/NEJM197609022951001. [DOI] [PubMed] [Google Scholar]
  14. Habif D. V., Lipton R., Cantell K. Interferon crosses blood-cerebrospinal fluid barrier in monkeys. Proc Soc Exp Biol Med. 1975 May;149(1):287–289. doi: 10.3181/00379727-149-38790. [DOI] [PubMed] [Google Scholar]
  15. Hill D. A., Baron S., Perkins J. C., Worthington M., Van Kirk J. E., Mills J., Kapikian A. Z., Chanock R. M. Evaluation of an interferon inducer in viral respiratory disease. JAMA. 1972 Feb 28;219(9):1179–1184. [PubMed] [Google Scholar]
  16. Ho M., Armstrong J. A. Interferon. Annu Rev Microbiol. 1975;29:131–161. doi: 10.1146/annurev.mi.29.100175.001023. [DOI] [PubMed] [Google Scholar]
  17. Jordan G. W., Fried R. P., Merigan T. C. Administration of human leukocyte interferon in herpes zoster. I. Safety, circulating, antiviral activity, and host responses to infection. J Infect Dis. 1974 Jul;130(1):56–62. doi: 10.1093/infdis/130.1.56. [DOI] [PubMed] [Google Scholar]
  18. Kern E. R., Overall J. C., Jr, Glasgow L. A. Herpesvirus hominis infection in newborn mice: treatment with interferon inducer polyinosinic-polycytidylic acid. Antimicrob Agents Chemother. 1975 Jun;7(6):793–800. doi: 10.1128/aac.7.6.793. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Lerner A. M., Bailey E. J. Differential sensitivity of herpes simplex virus types 1 and 2 to human interferon: antiviral effects of interferon plus 9-beta-D-arabinofuranosyladenine. J Infect Dis. 1976 Oct;134(4):400–404. doi: 10.1093/infdis/134.4.400. [DOI] [PubMed] [Google Scholar]
  20. Levy H. B., Baer G., Baron S., Buckler C. E., Gibbs C. J., Iadarola M. J., London W. T., Rice J. A modified polyriboinosinic-polyribocytidylic acid complex that induces interferon in primates. J Infect Dis. 1975 Oct;132(4):434–439. doi: 10.1093/infdis/132.4.434. [DOI] [PubMed] [Google Scholar]
  21. Levy H. B. Induction of interferon in vivo by polynucleotides. Tex Rep Biol Med. 1977;35:91–98. [PubMed] [Google Scholar]
  22. Merigan T. C., Rand K. H., Pollard R. B., Abdallah P. S., Jordan G. W., Fried R. P. Human leukocyte interferon for the treatment of herpes zoster in patients with cancer. N Engl J Med. 1978 May 4;298(18):981–987. doi: 10.1056/NEJM197805042981801. [DOI] [PubMed] [Google Scholar]
  23. Merigan T. C., Reed S. E., Hall T. S., Tyrrell D. A. Inhibition of respiratory virus infection by locally applied interferon. Lancet. 1973 Mar 17;1(7803):563–567. doi: 10.1016/s0140-6736(73)90714-9. [DOI] [PubMed] [Google Scholar]
  24. Nordlund J. J., Wolff S. M., Levy H. B. Inhibition of biologic activity of poly I: poly C by human plasma. Proc Soc Exp Biol Med. 1970 Feb;133(2):439–444. doi: 10.3181/00379727-133-34492. [DOI] [PubMed] [Google Scholar]
  25. Oie H. K., Buckler C. E., Uhlendorf C. P., Hill D. A., Baron S. Improved assays for a variety of interferons. 1. Proc Soc Exp Biol Med. 1972 Sep;140(4):1178–1181. doi: 10.3181/00379727-140-36636. [DOI] [PubMed] [Google Scholar]
  26. Solov'ev V. D. The results of controlled observations on the prophylaxis of influenza with interferon. Bull World Health Organ. 1969;41(3):683–688. [PMC free article] [PubMed] [Google Scholar]
  27. Southern P. M., Jr, Smith J. W., Luby J. P., Barnett J. A., Sanford J. P. Clinical and laboratory features of epidemic St. Louis encephalitis. Ann Intern Med. 1969 Oct;71(4):681–689. doi: 10.7326/0003-4819-71-4-681. [DOI] [PubMed] [Google Scholar]
  28. Strander H., Cantell K., Carlström G., Ingimarsson S., Jakobsson P., Nilsonne U. Acute infections in interferon-treated patients with osteosarcoma: preliminary report of a comparative study. J Infect Dis. 1976 Jun;133 (Suppl):A245–A248. doi: 10.1093/infdis/133.supplement_2.a245. [DOI] [PubMed] [Google Scholar]
  29. Strander H., Cantell K., Carlström G., Jakobsson P. A. Clinical and laboratory investigations on man: systemic administration of potent interferon to man. J Natl Cancer Inst. 1973 Sep;51(3):733–742. doi: 10.1093/jnci/51.3.733. [DOI] [PubMed] [Google Scholar]
  30. Stringfellow D. A., Overall J. C., Jr, Glasgow L. A. Interferon inducers in therapy of infection with encephalomyocarditis virus in mice. I. Effect of single doses of polyriboinosinic-polyribocytidylic acid and tilorone hydrochloride on viral pathogenesis. J Infect Dis. 1974 Nov;130(5):470–480. doi: 10.1093/infdis/130.5.470. [DOI] [PubMed] [Google Scholar]
  31. Tukey J. W. Some thoughts on clinical trials, especially problems of multiplicity. Science. 1977 Nov 18;198(4318):679–684. doi: 10.1126/science.333584. [DOI] [PubMed] [Google Scholar]
  32. Vilcek J., Havell E. A., Kohase M. Superinduction of interferon with metabolic inhibitors: possible mechanisms and practical applications. J Infect Dis. 1976 Jun;133 (Suppl):A22–A29. doi: 10.1093/infdis/133.supplement_2.a22. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES